News
UCBJF
281.70
NaN%
--
Belgian pharma UCB to buy U.S.-based Neurona for up to $1.15B
Seeking Alpha · 2d ago
UCB to acquire Neurona Therapeutics
TipRanks · 2d ago
Barclays Remains a Buy on UCB SA (0NZT)
TipRanks · 6d ago
Barclays Sticks to Their Buy Rating for UCB SA (0NZT)
TipRanks · 04/08 06:54
Barclays Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 03/30 06:35
Barclays Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 03/23 10:45
TD Cowen Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 03/20 18:25
Berenberg Bank Reaffirms Their Buy Rating on UCB SA (0NZT)
TipRanks · 03/17 06:26
UCB SA (0NZT) Gets a Buy from Barclays
TipRanks · 03/16 07:36
PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors
Seeking Alpha · 03/16 03:25
TD Cowen Keeps Their Buy Rating on UCB SA (0NZT)
TipRanks · 03/13 08:25
UCB SA (0NZT) Receives a Hold from Kepler Capital
TipRanks · 03/13 01:39
Barclays Sticks to Their Buy Rating for UCB SA (0NZT)
TipRanks · 03/12 06:37
AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis
Seeking Alpha · 03/11 12:31
Barclays Sticks to Their Buy Rating for UCB SA (0NZT)
TipRanks · 03/09 08:06
UCB downgraded to Equal Weight from Overweight at Morgan Stanley
TipRanks · 03/06 09:45
Goldman Sachs Keeps Their Buy Rating on UCB SA (0NZT)
TipRanks · 03/03 07:06
Kepler Capital Sticks to Their Hold Rating for UCB SA (0NZT)
TipRanks · 02/28 01:50
Barclays Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 02/27 07:49
UCB SA Non-GAAP EPS of €9.99, revenue of €7.74B; introduces FY26 outlook
Seeking Alpha · 02/26 06:51
More
Webull provides a variety of real-time UCBJF stock news. You can receive the latest news about Ucb Sa through multiple platforms. This information may help you make smarter investment decisions.
About UCBJF
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.